{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:00:19Z","timestamp":1794960019633,"version":"4.9.1"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"unspecified","delay-in-days":92,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017974","name":"Child Mind Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017974","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundo de Incentivo \u00e0 Pesquisa\/Hospital de Cl\u00ednicas de Porto Alegre","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2023,4,7]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Question<\/jats:title>\n                  <jats:p>Randomised controlled trials assessing treatments for anxiety, obsessive-compulsive and stress-related disorders often present high placebo response rates in placebo groups. Understanding the placebo response is essential in accurately estimating the benefits of pharmacological agents; nevertheless, no studies have evaluated the placebo response across these disorders using a lifespan approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study selection and analysis<\/jats:title>\n                  <jats:p>We searched MEDLINE, PsycINFO, Embase, Cochrane, websites of regulatory agencies and international registers from inception to 9 September 2022. The primary outcome was the aggregate measure of internalising symptoms of participants in the placebo arms of randomised controlled trials designed to assess the efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) in individuals diagnosed with anxiety, obsessive-compulsive or stress-related disorders. The secondary outcomes were placebo response and remission rates. Data were analysed through a three-level meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>We analysed 366 outcome measures from 135 studies (n=12 583). We found a large overall placebo response (standardised mean difference (SMD)=\u22121.11, 95% CI \u22121.22 to \u22121.00). The average response and remission rates in placebo groups were 37% and 24%, respectively. Larger placebo response was associated with a diagnosis of generalised anxiety disorder and post-traumatic stress disorder, when compared with panic, social anxiety and obsessive-compulsive disorder (SMD range, 0.40\u20130.49), and with absence of a placebo lead-in period (SMD=0.44, 95% CI 0.10 to 0.78). No significant differences were found in placebo response across age groups. We found substantial heterogeneity and moderate risk of bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Placebo response is substantial in SSRI and SNRI trials for anxiety, obsessive-compulsive and stress-related disorders. Clinicians and researchers should accurately interpret the benefits of pharmacological agents in contrast to placebo response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42017069090.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjment-2022-300630","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:01:37Z","timestamp":1683198097000},"page":"e300630","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis"],"prefix":"10.1136","volume":"26","author":[{"given":"Luis Souza","family":"Motta","sequence":"first","affiliation":[{"name":"Section of Negative Affect and Social Processes, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natan Pereira","family":"Gosmann","sequence":"additional","affiliation":[{"name":"Section of Negative Affect and Social Processes, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Postgraduate Program in Psychiatry and Behavioral Sciences, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Anxiety Disorders Outpatient Program, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna de Abreu","family":"Costa","sequence":"additional","affiliation":[{"name":"Anxiety Disorders Outpatient Program, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-7764","authenticated-orcid":false,"given":"Marianna de Barros","family":"Jaeger","sequence":"additional","affiliation":[{"name":"Anxiety Disorders Outpatient Program, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Frozi","sequence":"additional","affiliation":[{"name":"Section of Negative Affect and Social Processes, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1277-4340","authenticated-orcid":false,"given":"Laura Tietzmann","family":"Grevet","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-7420","authenticated-orcid":false,"given":"Lucas","family":"Spanemberg","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele Gus","family":"Manfro","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Psychiatry and Behavioral Sciences, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Anxiety Disorders Outpatient Program, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-2743","authenticated-orcid":false,"given":"Pim","family":"Cuijpers","sequence":"additional","affiliation":[{"name":"Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Samuel","family":"Pine","sequence":"additional","affiliation":[{"name":"Emotion and Development Branch, Section on Development and Affective Neuroscience, National Institute of Mental Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Salum","sequence":"additional","affiliation":[{"name":"Section of Negative Affect and Social Processes, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Postgraduate Program in Psychiatry and Behavioral Sciences, Hospital de Cl\u00ednicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"National Institute of Developmental Psychiatry for Children and Adolescents (INCT-CNPq), S\u00e3o Paulo, Brazil"},{"name":"Child Mind Institute, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"2025082702325560000_26.1.e300630.1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/da.22433","article-title":"Influence of study design on treatment response in anxiety disorder clinical trials","volume":"32","author":"Rutherford","year":"2015","journal-title":"Depress Anxiety"},{"key":"2025082702325560000_26.1.e300630.2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","article-title":"Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies","volume":"3","author":"Furukawa","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2025082702325560000_26.1.e300630.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3923"},{"key":"2025082702325560000_26.1.e300630.4","doi-asserted-by":"publisher","DOI":"10.1159\/000069738"},{"key":"2025082702325560000_26.1.e300630.5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2018.05.009","article-title":"60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: meta-regression of predictors of placebo response","volume":"201","author":"Leucht","year":"2018","journal-title":"Schizophr Res"},{"key":"2025082702325560000_26.1.e300630.6","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41386-019-0440-6","article-title":"Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacol"},{"key":"2025082702325560000_26.1.e300630.7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1111"},{"key":"2025082702325560000_26.1.e300630.8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1089\/cap.2015.0192","article-title":"Placebo response in pediatric anxiety disorders: implications for clinical trial design and interpretation","volume":"26","author":"Dobson","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2025082702325560000_26.1.e300630.9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jad.2017.04.068","article-title":"Obsessive-Compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis","volume":"218","author":"Sugarman","year":"2017","journal-title":"J Affect Disord"},{"key":"2025082702325560000_26.1.e300630.10","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291704003873"},{"key":"2025082702325560000_26.1.e300630.11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/pr.2016.181","article-title":"Is the perceived placebo effect comparable between adults and children? A meta-regression analysis","volume":"81","author":"Janiaud","year":"2017","journal-title":"Pediatr Res"},{"key":"2025082702325560000_26.1.e300630.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067606","article-title":"Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US food and drug administration: individual participant data analysis","volume":"378","author":"Stone","year":"2022","journal-title":"BMJ"},{"key":"2025082702325560000_26.1.e300630.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-018-1244-7"},{"key":"2025082702325560000_26.1.e300630.14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/cap.2019.0022","article-title":"The impact of placebo response rates on clinical trial outcome: a systematic review and meta-analysis of antidepressants in children and adolescents with major depressive disorder","volume":"29","author":"Li","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2025082702325560000_26.1.e300630.15","doi-asserted-by":"publisher","DOI":"10.1037\/a0034733"},{"key":"2025082702325560000_26.1.e300630.16","first-page":"4","article-title":"Update on the use of SSRIs and snris with children and adolescents in clinical practice","volume":"25","author":"Jane Garland","year":"2016","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"2025082702325560000_26.1.e300630.17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis","volume":"74","author":"Locher","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2025082702325560000_26.1.e300630.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002632","article-title":"Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials","volume":"3","author":"Cohen","year":"2008","journal-title":"PLoS One"},{"key":"2025082702325560000_26.1.e300630.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003664","article-title":"Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: a 3-level network meta-analysis","volume":"18","author":"Gosmann","year":"2021","journal-title":"PLoS Med"},{"key":"2025082702325560000_26.1.e300630.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.03.001"},{"key":"2025082702325560000_26.1.e300630.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025082702325560000_26.1.e300630.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"key":"2025082702325560000_26.1.e300630.23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jrsm.35","article-title":"Fixed effects and variance components estimation in three-level meta-analysis","volume":"2","author":"Konstantopoulos","year":"2011","journal-title":"Res Synth Methods"},{"key":"2025082702325560000_26.1.e300630.24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1017\/S2045796016000809","article-title":"Pre-post effect sizes should be avoided in meta-analyses","volume":"26","author":"Cuijpers","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2025082702325560000_26.1.e300630.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.06.006"},{"key":"2025082702325560000_26.1.e300630.26","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2021","journal-title":"J Stat Soft"},{"key":"2025082702325560000_26.1.e300630.27","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000078"},{"key":"2025082702325560000_26.1.e300630.28","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.173450"},{"key":"2025082702325560000_26.1.e300630.29","first-page":"107","article-title":"Placebo response in clinical trials with schizophrenia patients","volume":"24","author":"Kinon","year":"2011","journal-title":"Curr Opin Psychiatry"},{"key":"2025082702325560000_26.1.e300630.30","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2009.0047"},{"key":"2025082702325560000_26.1.e300630.31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12040474"},{"key":"2025082702325560000_26.1.e300630.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2010.06.001"},{"key":"2025082702325560000_26.1.e300630.33","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6394(2000)12:4<217::AID-DA5>3.0.CO;2-6"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2022-300630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:33:06Z","timestamp":1756287186000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2022-300630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,4]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjment-2022-300630"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2022-300630","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}